Starpharma (OTCMKTS:SPHRY) Stock Price Down 4.2% – Time to Sell?

Starpharma Holdings Ltd. (OTCMKTS:SPHRYGet Free Report) fell 4.2% on Friday . The stock traded as low as $2.10 and last traded at $2.30. 250 shares changed hands during mid-day trading, a decline of 89% from the average session volume of 2,278 shares. The stock had previously closed at $2.40.

Starpharma Stock Performance

The business has a 50 day moving average of $1.61 and a 200-day moving average of $0.98. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.95 and a current ratio of 4.32.

About Starpharma

(Get Free Report)

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. The company offers VivaGel BV, a non-antibiotic vaginal gel for the treatment of bacterial vaginosis and prevention of recurrent BV; VIRALEZE, an antiviral nasal spray; and VivaGel condom, an antiviral condom.

Featured Articles

Receive News & Ratings for Starpharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Starpharma and related companies with MarketBeat.com's FREE daily email newsletter.